ADC Therapeutics Secures $60 Million PIPE Financing to Fuel ZYNLONTA® Expansion
LAUSANNE, Switzerland – October 13, 2025 – ADC Therapeutics SA (NYSE: ADCT), a commercial-stage leader in the field of Antibody Drug Conjugates (ADCs), announced today a significant capital boost, securing $60.0 million through a private investment in public equity (PIPE) financing. This strategic move is designed to strengthen the company’s financial position and accelerate the commercial trajectory of its flagship drug, ZYNLONTA® (loncastuximab tesirine-lpyl).
Key Details of the Private Placement
The $60 million financing round saw participation from prominent investors, underscoring strong confidence in ADC Therapeutics’ proprietary ADC technology platform.
- Lead Investor: The PIPE was led by TCGX, with key participation from Redmile Group and several other existing institutional investors.
- Securities Sold: ADC Therapeutics is selling approximately 11.3 million common shares at $4.00 per share and 3.8 million pre-funded warrants at $3.90 per warrant.
- Expected Closing: The transaction is anticipated to close on October 27, 2025, subject to standard closing conditions.
Strategic Use of Proceeds
The net proceeds from the PIPE financing, estimated to be approximately $57.6 million, will be strategically deployed to enhance the company’s long-term growth and stability.
According to Ameet Mallik, Chief Executive Officer of ADC Therapeutics, the financing "enhances our ability to prepare for and execute the potential relaunch of ZYNLONTA in 2027 and further strengthens our balance sheet relative to our previously disclosed cash runway into 2028."
The company intends to use the capital to:
Invest in the commercial expansion of ZYNLONTA®.
Strengthen the balance sheet and extend its cash runway.
Fund working capital and general corporate purposes.
This financing positions ADC Therapeutics to capitalize on upcoming data catalysts expected later this year and throughout 2026, accelerating its path toward long-term sustainable growth.
Financial Outlook and Cash Position
The financing significantly bolsters ADC Therapeutics’ liquidity. The company provided preliminary unaudited financial estimates for the third quarter ended September 30, 2025:
- Q3 2025 ZYNLONTA® Net Product Revenues: Approximately $15.8 million.
- Cash and Cash Equivalents (Pre-PIPE): $234.7 million as of September 30, 2025.
- Pro Forma Cash and Cash Equivalents (Post-PIPE): Approximately $292.3 million, giving effect to the estimated net proceeds.
About ZYNLONTA® (loncastuximab tesirine-lpyl)
ZYNLONTA is a cutting-edge CD19-directed Antibody Drug Conjugate (ADC). Its mechanism of action involves delivering a potent pyrrolobenzodiazepine (PBD) payload directly to CD19-expressing tumor cells, causing DNA binding and eventual tumor cell death.
ZYNLONTA is a crucial treatment option for adults with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL). The drug holds accelerated approval from the U.S. FDA and conditional approval from the European Medicines Agency (EMA), and is also being evaluated in combination studies for other B-cell malignancies and earlier lines of therapy.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a global pioneer dedicated to transforming the cancer treatment paradigm through its proprietary ADC technology. Based in Lausanne, Switzerland, the company focuses on advancing ADCs for both hematologic malignancies and solid tumors, building a robust pipeline in addition to its commercialized asset, ZYNLONTA®.
Nenhum comentário